

NEWS RELEASE

Interprotein Announces Collaborative Research Agreement with IWAKI SEIYAKU for Anti-COVID-19 Drug Discovery

April 8th, 2021 – Interprotein Corporation (Interprotein) today announces that Interprotein and IWAKI SEIYAKU CO., LTD. (IWAKI SEIYAKU) entered into a collaborative research agreement. The partnership will focus on drug discovery research for COVID-19.

Under the agreement, Interprotein and IWAKI SEIYAKU will collaborate to contribute to the treatment for COVID-19 by efficient identification of potent and orally active 3CLpro (main protease) inhibitors, combining Interprotein's platform technology, AI-guided INTENDD® and the excellent compound synthesis technology of IWAKI SEIYAKU. Both the companies plan to conduct the speedy lead optimization of small molecule anti-COVID-19 drug with the difficulty of synthesis by matching up approaches of drug repurposing and drug discovery in the present collaboration.

About Interprotein:

Interprotein is conducting drug discovery research of small molecule medicines and conformationally-constrained therapeutic peptides based on an AI-introduced activity prediction system, AI-guided INTENDD® (INTerprotein's Engine for New Drug Design) and HLHP (Helix-Loop-Helix Peptide) technology, respectively. AI-guided INTENDD® enables to precisely predict activities of small molecule ligands based on 3D structures of drug target proteins and the ligands. Interprotein is comprehensively putting effort into the treatment for COVID-19 through NKG2A inhibition by HLHP as well as 3CLpro inhibition by drug repurposing and NCEs.

<http://www.interprotein.com/>

Contact:

Interprotein Corporation R&D and BD Division Hirotsugu KOMATSU, Ph.D. E-mail: komatsu@interprotein.com
